Most Clicked StoriesMore >


Biogen moves closer to spinning off hemophilia business

BIO SmartBrief | Jan 17, 2017

Bioverativ will be spun off from Biogen, and the management team of the hemophilia enterprise plans to pursue partnerships. The spinoff is not intended to draw bids from potential buyers, said John Cox, who will lead the new company. FiercePharma (01/11)


Forward Pharma gains $1.25B from Biogen for patent settlement agreement

BIO SmartBrief | Jan 18, 2017

Merck KGaA gains 4 Vertex cancer programs

BIO SmartBrief | Jan 16, 2017

Eli Lilly to spend about $960M for acquisition of CoLucid Pharmaceuticals

BIO SmartBrief | Jan 19, 2017

Sanofi gains license to ImmuNext's autoimmune disease therapy

BIO SmartBrief | Jan 17, 2017

Biosimilar interchangeability draft guidance released by FDA

BIO SmartBrief | Jan 18, 2017

FDA fast-tracks TapImmune's ovarian cancer drug study

BIO SmartBrief | Jan 17, 2017

Gene-edited potatoes, soybeans may soon reach market

BIO SmartBrief | Jan 16, 2017

Humira biosimilar from Boehringer accepted for FDA, EMA review

BIO SmartBrief | Jan 19, 2017

Cytori to buy nanoparticle platform, cancer drugs from Azaya

BIO SmartBrief | Jan 20, 2017


Find BIO SmartBrief Issues by Date:



BIO News More >


Register for the 2017 BIO CEO & Investor Conference in NYC

BIO SmartBrief | Jan 20, 2017

Registration is open for the 2017 BIO Asia International Conference

BIO SmartBrief | Jan 20, 2017

Save on Airgas

BIO SmartBrief | Jan 19, 2017

BIO Asia International Conference

BIO SmartBrief | Jan 19, 2017

Nikon

BIO SmartBrief | Jan 18, 2017




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more